Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Unlimited Watchlists, Portfolios, Screeners, and other Barchart tools. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Logicbio Therapeutics Inc (LOGC)

Logicbio Therapeutics Inc (LOGC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 68,233
  • Shares Outstanding, K 32,963
  • Annual Sales, $ 5,410 K
  • Annual Income, $ -40,030 K
  • 60-Month Beta 4.61
  • Price/Sales 12.55
  • Price/Cash Flow N/A
  • Price/Book 4.34
Trade LOGC with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.94
  • Most Recent Earnings -0.18 on 11/14/22
  • Next Earnings Date 11/21/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 5.57%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.22
  • Number of Estimates 1
  • High Estimate -0.22
  • Low Estimate -0.22
  • Prior Year -0.28
  • Growth Rate Est. (year over year) +21.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.03 +1.97%
on 10/17/22
2.07 unch
on 11/15/22
+0.02 (+0.98%)
since 10/14/22
3-Month
0.26 +704.51%
on 09/28/22
2.07 unch
on 11/15/22
+1.55 (+301.94%)
since 08/15/22
52-Week
0.26 +704.51%
on 09/28/22
3.77 -45.09%
on 11/16/21
-1.45 (-41.19%)
since 11/15/21

Most Recent Stories

More News
Alexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio® Therapeutics

Alexion, AstraZeneca Rare Disease, today announced the completion of its acquisition of LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a pioneering genomic medicine company.

AZN : 66.17 (+0.08%)
LOGC : 2.07 (+0.49%)
LogicBio Therapeutics: Q3 Earnings Snapshot

LogicBio Therapeutics: Q3 Earnings Snapshot

LOGC : 2.07 (+0.49%)
LogicBio Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates

/PRNewswire/ -- LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a clinical-stage genetic medicine company, today reported financial results for the third quarter...

LOGC : 2.07 (+0.49%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BTRS, JVA, AKUS, LOGC

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

BTRS : 9.45 (unch)
JVA : 2.38 (+2.36%)
AKUS : 13.20 (+0.23%)
LOGC : 2.07 (+0.49%)
SHAREHOLDER ALERT: Weiss Law Reminds LOGC, POSH, AERC, and BTRS Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

LOGC : 2.07 (+0.49%)
POSH : 17.80 (+0.06%)
AERC : 3.38 (+3.68%)
BTRS : 9.45 (unch)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AAWW, LOGC, RFP, PBFX, RNWK

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

AAWW : 100.66 (-0.26%)
LOGC : 2.07 (+0.49%)
RFP : 21.18 (+0.09%)
PBFX : 21.55 (-1.19%)
RNWK : 0.7158 (-0.45%)
LOGICBIO® THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LogicBio® Therapeutics, Inc. - LOGC

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of LogicBio® Therapeutics, Inc. (NasdaqGM: LOGC)...

LOGC : 2.07 (+0.49%)
SHAREHOLDER ALERT: Weiss Law Reminds LOGC, POSH, AERC, and BTRS Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

LOGC : 2.07 (+0.49%)
POSH : 17.80 (+0.06%)
AERC : 3.38 (+3.68%)
BTRS : 9.45 (unch)
Central Nervous System Disorders Therapeutics Market Expected to Reach $159 Billion by 2028

Palm Beach, FL –– October 12, 2022 – FinancialNewsMedia.com News Commentary – The COVID pandemic has not only had a negative effect on most markets but it has also spurred growth in several worldwide...

KTTA : 1.0100 (-0.98%)
AZN : 66.17 (+0.08%)
LOGC : 2.07 (+0.49%)
CRDF : 1.3900 (+0.72%)
SWTX : 23.83 (-2.66%)
DAWN : 21.41 (+1.28%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LOTZ, LOGC, OIIM, JVA

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

LOTZ : 0.1801 (+0.06%)
LOGC : 2.07 (+0.49%)
OIIM : 4.43 (+0.23%)
JVA : 2.38 (+2.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

LogicBio Therapeutics Inc. is a genome editing company. It focuses on developing medicines to treat rare diseases in patients with significant unmet medical needs. The company's technology platform consists of GeneRide(TM). LogicBio Therapeutics Inc. is based in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 2.08
2nd Resistance Point 2.08
1st Resistance Point 2.07
Last Price 2.07
1st Support Level 2.06
2nd Support Level 2.06
3rd Support Level 2.05

See More

52-Week High 3.77
Fibonacci 61.8% 2.43
Last Price 2.07
Fibonacci 50% 2.01
Fibonacci 38.2% 1.60
52-Week Low 0.26

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar